Highlights

  • Consensus rating of Hold from 9 analysts: 1 Buy or equivalent, 5 Hold, 3 Sell or equivalent.
  • Mean price target of A$0.47 against a share price of A$0.40 on 8 October 2026, an implied upside of 16.4%.
  • Analyst targets range from A$0.35 to A$0.73.
  • Healius (ASX:HLS) announced on 25 September 2026 a binding agreement to sell its Wholly Owned Subsidiary Agilex Biolabs to a subsidiary of Novotech Health Holdings for an Enterprise value of A$160 million.

Healius (ASX:HLS) carries a consensus analyst rating of Hold. Of the 9 analyst recommendations recorded, 1 is Buy or equivalent, 5 are Hold and 3 are Sell or equivalent. The mean price target is A$0.47, with targets ranging from A$0.35 to A$0.73, against a current share price of A$0.40 (8 October 2026). Healius Limited is an Australian pathology services provider that also owned the clinical research Business Agilex Biolabs.

Company name

Healius

Ticker

(ASX:HLS)

Exchange

ASX (Australian Securities Exchange)

Current share price

A$0.40

Price date

8 October 2026

Number of analysts

9

Rating consensus

Hold

Consensus price target (mean)

A$0.47

Highest target

A$0.73

Lowest target

A$0.35

Implied upside/downside to mean target

Implied upside of 16.4%

Latest developments

Healius (ASX:HLS) announced on 25 September 2026 a binding agreement to sell its wholly owned subsidiary Agilex Biolabs to a subsidiary of Novotech Health Holdings for an enterprise value of A$160 million. On a pre-AASB 16 basis, the transaction represents 19.8 times Agilex Biolabs' FY2026 EBITDA. It is expected to result in cash proceeds of about $155 million after all separation and transaction costs, and Healius does not expect to incur tax on the transaction.

Completion is subject to customary conditions, including approval by the Foreign Investment Review Board and the Australian Competition and Consumer Commission, and is expected during the second half of FY2027. The company commenced the sale process in May 2026 in response to several unsolicited approaches. On completion, Healius will be in a net cash position and will provide details on the use of proceeds closer to completion. The company said the sale will not affect its Pathology operations.

Sector context

The sale narrows Healius to its core Pathology business, which the company says management can focus on growing. Clinical research services such as Agilex Biolabs operate separately from pathology testing.

Risks and what to watch

Completion is subject to FIRB and ACCC approvals and is not expected until the second half of FY2027. The company has not yet said how it will use the proceeds. Pathology Earnings depend on test volumes, funding and costs, and the consensus data shows a Hold rating.

Next milestones

Items to watch include FIRB and ACCC approvals, completion of the sale in the second half of FY2027, Healius's intentions for the sale proceeds, and the half-year result for the pathology business.